The phase 3 PROSERA study found that seralutinib demonstrates clear improvement in patients with PAH, according to a press release.

AI-enhanced forecasting helps retailers reduce waste, prevent stockouts, and protect margins with real-time, data-driven inventory planning.

Gossamer Bio (Nasdaq:GOSS) reported Q1 2026 results and key updates on seralutinib for PAH. An in‑person FDA Pre‑NDA Type B meeting is scheduled for mid‑June, with a planned NDA submission in September 2026 and potential FDA decision in Q3 2027.Exploratory PROSERA CT FRI data showed multiple nominally statistically significant multi‑compartment imaging effects correlated with clinical outcomes. Gossamer launched an exchange offer for its $200M 5.00% convertible notes, which upon full participation would cut convertible debt to $72M. Q1 cash was $99.2M, with runway into Q1 2027.

Gossamer Bio (Nasdaq: GOSS) reported FDA, strategic, and capital structure updates centered on seralutinib for pulmonary arterial hypertension (PAH). Following a mid‑June 2026 Type B Pre‑NDA meeting and receipt of minutes, Gossamer plans a September 2026 NDA submission for PAH, supported by Phase 3 PROSERA plus Phase 2 TORREY confirmatory evidence. If filed, an FDA decision could occur in 3Q 2027.Gossamer and Chiesi terminated their collaboration, returning worldwide development and commercial rights for seralutinib to Gossamer. Chiesi will make a $5 million one‑time payment and receive capped royalties and milestone payments, while Gossamer makes no upfront payment and regains full global operational control. At a July 14, 2026 special meeting, stockholders approved proposals tied to an exchange of $181.1 million (90.5%) of 5.00% Convertible Senior Notes due 2027 into $65.2 million of new 7.50% Convertible Senior Secured First Lien Notes due 2030 plus equity and warrants, reducing total debt principal by about $115.9 million. Stockholders also authorized a reverse stock split to support Nasdaq bid‑price compliance, expected to be effected in or shortly after 3Q 2026, subject to Board decision. Gossamer preliminarily reported $57 million in cash, cash equivalents and marketable securities as of June 30, 2026 and announced a same‑day business update webcast.

Enter our giveaway to win Prosera Dose Of Glow Vitamin C serum worth $88. Boost your beauty routine today!

Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.

Reported Monday, Feb 23 - 8:23am EST (TheFly subscription required to read more.)

Reported Monday, Jun 16 - 7:42am EDT (TheFly subscription required to read more.)

Gossamer Bio, Inc. is embroiled in a class action lawsuit after revealing the Phase 3 PROSERA trial results, affecting investor trust and stock price significantly.

Gossamer Bio, Inc. is under scrutiny as investors file a class action lawsuit alleging concealed risks regarding the PROSERA trial. The fallout from failed trial results has caused an 80% drop in stock prices.

A class action lawsuit against Gossamer Bio arises after a staggering 80% drop in stock due to trial failures on their drug for pulmonary arterial hypertension. Investors seek justice.

Gossamer Bio faces a securities class action lawsuit after serious alleged fraud regarding their PROSERA trial and placebo responses. Investors may seek to reclaim losses.

Robbins LLP has announced a class action lawsuit against Gossamer Bio for allegedly misleading shareholders regarding the PROSERA study results, which impacted stock prices significantly.

Gossamer Bio, Inc. suffers a significant drop in stock value following disappointing Phase 3 trials, raising concerns among investors and stakeholders.

Gossamer Bio's Phase 3 PROSERA trial results for seralutinib disappoint investors, leading to a significant drop in stock value. Insights into the implications are examined.

Gossamer Bio (Nasdaq: GOSS) reported Q4 and full-year 2025 results, provided a corporate update, and outlined next steps after PROSERA Phase 3 topline data.Key points: PROSERA narrowly missed its prespecified alpha at Week 24; prespecified higher‑risk and CTD‑PAH subgroups showed larger 6MWD gains. Enrollment in the PH‑ILD SERANATA study is paused. Year‑end cash and marketable securities were $136.9 million, funding operations into Q1 2027.

Gossamer Bio (NASDAQ: GOSS) reported third-quarter 2025 results and a program update on November 5, 2025. Key corporate facts: cash, cash equivalents and marketable securities of $180.2 million as of September 30, 2025, with management saying this provides runway into 2027. The Phase 3 PROSERA study completed enrollment at 390 PAH patients and topline results are expected in February 2026. The first site was activated for the registrational Phase 3 SERANATA study in PH‑ILD (~480 patients randomized across two doses and placebo). Q3 2025 revenue from Chiesi was $13.3M; net loss was $48.2M (Q3 2024: $30.8M).

Gossamer Bio (NASDAQ: GOSS) reported Q2 2025 financial results and provided updates on its lead drug candidate seralutinib. The company completed enrollment of 390 patients in its Phase 3 PROSERA study for PAH treatment, with topline results expected in February 2026. The study's primary endpoint is change in six-minute walk distance at week 24.Financial highlights include $212.9 million in cash and equivalents, expected to fund operations into 2027. Q2 revenue was $11.5 million, with a net loss of $38.3 million ($0.17 per share). The company is also preparing to launch the Phase 3 SERANATA study for PH-ILD in Q4 2025, targeting approximately 480 patients.

First-in-class PAH treatment reaches crucial Phase 3 milestone with 390 patients. See how this potential breakthrough could reshape treatment options. Get insights.